scholarly journals Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway

Aging Cell ◽  
2018 ◽  
Vol 17 (4) ◽  
pp. e12763 ◽  
Author(s):  
Lujin Wu ◽  
Ke Wang ◽  
Wei Wang ◽  
Zheng Wen ◽  
Peihua Wang ◽  
...  
Keyword(s):  
Diabetic Cardiomyopathy ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Cardiac Lipotoxicity

scholarly journals GW26-e0013 The effect and mechanism of Glucagon-like peptide-1 protects against the diabetic cardiomyopathy

2015 ◽  
Vol 66 (16) ◽  
pp. C97
Author(s):  
Qinan Wu ◽  
Xiaotian Lei ◽  
Xiaguang Gan ◽  
Wuquan Deng ◽  
Bing Chen ◽  
...  
Keyword(s):  
Diabetic Cardiomyopathy ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes

2013 ◽  
Vol 305 (3) ◽  
pp. H295-H304 ◽  
Author(s):  
Akio Monji ◽  
Toko Mitsui ◽  
Yasuko K. Bando ◽  
Morihiko Aoyama ◽  
Toshimasa Shigeta ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Type 2 Diabetes ◽  
Diabetic Cardiomyopathy ◽  
Cardiac Remodeling ◽  
Receptor Activation ◽  
Left Ventricular ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
And Oxidative Stress

Glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is a remedy for type 2 diabetes mellitus (T2DM). Ex-4 ameliorates cardiac dysfunction induced by myocardial infarction in preclinical and clinical settings. However, it remains unclear whether Ex-4 may modulate diabetic cardiomyopathy. We tested the impact of Ex-4 on two types of diabetic cardiomyopathy models, genetic (KK) and acquired T2DM induced by high-fat diet [diet-induced obesity (DIO)], to clarify whether Ex-4 may combat independently of etiology. Each type of mice was divided into Ex-4 (24 nmol·kg−1·day−1 for 40 days; KK-ex4 and DIO-ex4) and vehicle (KK-v and DIO-v) groups. Ex-4 ameliorated systemic and cardiac insulin resistance and dyslipidemia in both T2DM models. T2DM mice exhibited systolic (DIO-v) and diastolic (DIO-v and KK-v) left ventricular dysfunctions, which were restored by Ex-4 with reduction in left ventricular hypertrophy. DIO-v and KK-v exhibited increased myocardial fibrosis and steatosis (lipid accumulation), in which were observed cardiac mitochondrial remodeling and enhanced mitochondrial oxidative damage. Ex-4 treatment reversed these cardiac remodeling and oxidative stress. Cytokine array revealed that Ex-4-sensitive inflammatory cytokines were ICAM-1 and macrophage colony-stimulating factor. Ex-4 ameliorated myocardial oxidative stress via suppression of NADPH oxidase 4 with concomitant elevation of antioxidants (SOD-1 and glutathione peroxidase). In conclusion, GLP-1R agonism reverses cardiac remodeling and dysfunction observed in T2DM via normalizing imbalance of lipid metabolism and related inflammation/oxidative stress.

scholarly journals Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Jieyu Liu ◽  
Yu Liu ◽  
Li Chen ◽  
Yuehui Wang ◽  
Junqi Li
Keyword(s):  
Cardiac Function ◽  
Diabetic Cardiomyopathy ◽  
Caspase 3 ◽  
Mrna Levels ◽  
Caspase 12 ◽  
Before And After ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Endoplasmic Reticulum Stress Pathway ◽  
Stress Pathway

Aim. This study aimed to investigate whether the glucagon-like peptide-1 analog liraglutide (LIRA) can protect against diabetic cardiomyopathy and explore the related mechanism.Methods. Rats were divided into 6 groups: a nondiabetic group, diabetic cardiomyopathy rats without LIRA treatment, diabetic cardiomyopathy rats with LIRA treatment (with high-, medium-, and low-dose, resp.), and diabetic cardiomyopathy rats treated with insulin. Cardiac function was examined by echocardiography before and after treatment. The histopathology of the heart was examined with H&E staining. The mRNA levels of XBP1, ATF4, and TRAF2 were analyzed by RT-PCR, and the expression of glucose-regulated protein 78 (Grp78), enhancer-binding protein homologous protein (CHOP), caspase-3, and caspase-12 was detected by western blot.Results. LIRA strongly improved cardiac function from both echocardiographic and histopathologic analyses, but insulin only partly increased cardiac function by improving FS and LVPW values. LIRA treatment can significantly decrease the expression of XBP1, ATF4, and TRAF2 (P<0.01). LIRA also significantly downregulates the expression of Grp78, caspase-3 (P<0.01), CHOP, and caspase-12 (P<0.05).Conclusions. LIRA can protect against diabetic cardiomyopathy by inactivating the ER stress pathway. The improvement in cardiac function by LIRA is independent of glucose control.

scholarly journals Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy

2019 ◽  
pp. 18-22
Keyword(s):  
Diabetic Cardiomyopathy ◽  
Disease Process ◽  
Therapeutic Interventions ◽  
Second Line ◽  
Cardiovascular Outcome Trials ◽  
Short Period ◽  
Historical Importance ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Recent cardiovascular outcome trials (CVOTs) have transformed the landscape for the management of type 2 diabetes mellitus. In a remarkably short period of time, national and international guidelines have been overhauled to reflect the remarkable cardiovascular benefits of sodium/glucose linked transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor analogues (GLP-1RA) in mitigating cardiovascular risk. Both SGLT2is and GLP-1RAs remain second-line to metformin, reflecting the historical importance of this biguanide antihyperglycemic. In this review, these three very different antihyperglycemics are discussed in the light of CVOT data and of the preclinical data revealing remarkable pleiotropic signaling effects of these drugs. A model of diabetic cardiomyopathy is discussed, and the points of contact that these therapeutic interventions have upon this model may of help in understanding how each can be best targeted in this complex pathophysiological disease process.

Effects of glucagon-like peptide-1 (GLP-1) on gastric accommodation, emptying and satiety in humans

2001 ◽  
Vol 120 (5) ◽  
pp. A74-A74
Author(s):  
S AROS ◽  
D KIM ◽  
D BURTON ◽  
G THOMFORDE ◽  
A VELLA ◽  
...  
Keyword(s):  
Gastric Accommodation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Eine häufige genetische Variation in WFS1 bedingt eine gestörte Glucagon-like Peptide-1-induzierte Insulinsekretion

2009 ◽  
Vol 4 (S 01) ◽  
Author(s):  
K Müssig ◽  
SA Schäfer ◽  
H Staiger ◽  
F Machicao ◽  
N Stefan ◽  
...  
Keyword(s):  
Genetische Variation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document